Fulcrum Therapeutics’ (FULC) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright reissued their neutral rating on shares of Fulcrum Therapeutics (NASDAQ:FULC) in a report published on Wednesday,Benzinga reports. The brokerage currently has a $4.00 price objective on the stock.

Separately, Royal Bank of Canada reiterated a “sector perform” rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $9.33.

Fulcrum Therapeutics Stock Performance

Shares of FULC stock opened at $3.32 on Wednesday. Fulcrum Therapeutics has a fifty-two week low of $2.86 and a fifty-two week high of $13.70. The firm has a market cap of $179.08 million, a P/E ratio of -10.71 and a beta of 2.03. The business’s 50 day moving average price is $4.13 and its 200-day moving average price is $4.62.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.03). As a group, equities analysts predict that Fulcrum Therapeutics will post -0.16 EPS for the current year.

Institutional Investors Weigh In On Fulcrum Therapeutics

Several hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp lifted its holdings in shares of Fulcrum Therapeutics by 2.3% during the fourth quarter. Bank of New York Mellon Corp now owns 141,873 shares of the company’s stock valued at $667,000 after purchasing an additional 3,126 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in Fulcrum Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock valued at $43,000 after buying an additional 4,701 shares in the last quarter. American Century Companies Inc. increased its position in Fulcrum Therapeutics by 5.9% during the 4th quarter. American Century Companies Inc. now owns 120,611 shares of the company’s stock valued at $567,000 after buying an additional 6,770 shares in the last quarter. BNP Paribas Financial Markets purchased a new position in Fulcrum Therapeutics during the fourth quarter valued at $38,000. Finally, Wells Fargo & Company MN boosted its holdings in Fulcrum Therapeutics by 34.4% in the fourth quarter. Wells Fargo & Company MN now owns 34,264 shares of the company’s stock worth $161,000 after acquiring an additional 8,761 shares in the last quarter. Institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.